Skip to main content
TipRanks
Go Ultimate75% OFF

Compare Gyre Therapeutics (L9S) vs. Competitors

1 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
DE:L9SGyre TherapeuticsEUR 3.82EUR 449.84M-15.45-44.64%Moderate BuyUnlock the DE:L9S analyst price target with TipRanks PremiumDE:L9SUnlock the DE:L9S top-analyst price target with TipRanks Premium
GALTGalectin Therapeutics$3.05$316.67M-7.14-44.85%Moderate BuyUnlock the GALT analyst price target with TipRanks PremiumDE:L9S vs GALTUnlock the GALT top-analyst price target with TipRanks Premium
IVAInventiva$3.68$944.92M-6.40-3.66%Strong BuyUnlock the IVA analyst price target with TipRanks PremiumDE:L9S vs IVAUnlock the IVA top-analyst price target with TipRanks Premium
SGMTSagimet Biosciences, Inc. Class A$10.22$768.83M-8.5932.04%Strong BuyUnlock the SGMT analyst price target with TipRanks PremiumDE:L9S vs SGMTUnlock the SGMT top-analyst price target with TipRanks Premium
AVLNAvalyn Pharma Inc$30.28$1.36B-17.112.68%Moderate BuyUnlock the AVLN analyst price target with TipRanks PremiumDE:L9S vs AVLNUnlock the AVLN top-analyst price target with TipRanks Premium
VCREVicore Pharma Holding AB Sponsored ADR$10.36$306.94M-5.70-23.05%Strong BuyUnlock the VCRE analyst price target with TipRanks PremiumDE:L9S vs VCREUnlock the VCRE top-analyst price target with TipRanks Premium

Performance Comparison

-75%-50%-25%0%25%50%75%100%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
DE:L9SGyre Therapeutics3.82-3.03-44.23%
GALTGalectin Therapeutics3.05-2.95-49.17%
IVAInventiva3.68-0.38-9.36%
SGMTSagimet Biosciences, Inc. Class A10.222.4130.86%
AVLNAvalyn Pharma Inc30.280.792.68%
VCREVicore Pharma Holding AB Sponsored ADR10.36-3.10-23.05%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts